A TEM to kill

Novartis AG and the National Cancer Institute have developed mAbs against anthrax toxin receptor 1 that inhibit tumor angiogenesis in multiple mouse models of cancer with fewer side effects than anti-VEGF therapies.¹ A key next step is to determine how widely the target is expressed in human tumor samples.

Drugs that block VEGF signaling do not differentiate between tumors and healthy blood vessels, and thus they can cause side effects including delayed wound healing, pulmonary hemorrhage and gastrointestinal perforation...